COMMUNIQUÉS West-GlobeNewswire

DBV Technologies Publie son Document de Référence 2018 et son « Form 20-F » américain
01/04/2019
Montrouge, France, le 1 avril (23 :00 CET) 2019 DBV Technologies Publie son Document de Référence 2018 et son « Form 20-F » américain DBV Technologies (Euronext : DBV – ISIN : FR0010417345 - Nasdaq : DBVT), une société [...]
EDAP TMS SA : EDAP Reports Q4 and Full Year 2018 Results
01/04/2019
Reports record revenues for the fifth consecutive year Record fiscal year 2018 revenues of €39.2 million Q4 2018 HIFU net sales increased 79% year-over-year Profitable and cash flow positive during the fourth quarter of [...]
Daré Bioscience, Inc. Regains Listing Compliance on Nasdaq
01/04/2019
SAN DIEGO, April 01, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.(NASDAQ: DARE), a leader in women’s health innovation, today announced that it received notice from The Nasdaq Stock Market LLC indicating that the [...]
Altimmune Announces Financial Results for the Year Ended December 31, 2018 and Provides Corporate Update
01/04/2019
Conference call and webcast scheduled for tomorrow, Tuesday, April 2, at 8:30 am Eastern Time GAITHERSBURG, Md., April 01, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics [...]
Supernus Announces Webcast of Investor Day on April 16, 2019
01/04/2019
ROCKVILLE, Md., April 01, 2019 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system [...]
Precision Therapeutics Reports Year End 2018 Financial Results and Provides Corporate Update
01/04/2019
MINNEAPOLIS, April 01, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to Women’s Oncology, announced today [...]
Atara Biotherapeutics Presents Off-the-Shelf, Allogeneic CAR T Preclinical Results at the American Association of Cancer Research (AACR) Annual Meeting 2019
01/04/2019
Epstein-Barr virus-specific T cells were engineered to express second-generation CD19 chimeric antigen receptors, eliminated in vitro alloreactivity and inhibited tumor growth in an animal model Off-the-shelf, [...]
AveXis expands world-leading gene therapy manufacturing capacity with purchase of advanced biologics therapy manufacturing campus in Longmont, Colorado
01/04/2019
Facility to become the largest of four state-of-the-art sites involved in manufacturing of AveXis gene therapies for pipeline of rare genetic diseases including spinal muscular atrophy AveXis plans to offer positions to [...]
BeiGene Announces Phase 1 Long-Term Exposure Data and Results from Structural and Mechanistic Analyses on Tislelizumab at the AACR Annual Meeting
01/04/2019
CAMBRIDGE, Mass. and BEIJING, China, April 01, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative [...]
Wright Medical Group N.V. to Present at Needham Healthcare Conference
01/04/2019
Wednesday, April 10, 2019 at 12:00 p.m. Eastern Time AMSTERDAM, The Netherlands, April 01, 2019 (GLOBE NEWSWIRE) -- Wright Medical Group N.V. (NASDAQ: WMGI) announced today that it will present at the Needham Healthcare [...]
Precision BioSciences Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
01/04/2019
DURHAM, N.C., April 01, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS genome editing platform, [...]
Adverum Biotechnologies Appoints Ophthalmology Industry Veteran Aaron Osborne, MBBS MRCOphth, as Chief Medical Officer
01/04/2019
MENLO PARK, Cali., April 01, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the [...]
Align Technology to Announce First Quarter 2019 Results on April 24, 2019
01/04/2019
SAN JOSE, Calif., April 01, 2019 (GLOBE NEWSWIRE) -- Align Technology, Inc. (Nasdaq: ALGN) announced today that the Company will report first quarter 2019 financial results on Wednesday, April 24, 2019 after the close [...]
Nkarta Therapeutics Presents Data at AACR Demonstrating Proprietary NK Cell Engineering and Expansion Technology Enhances Potency and Cytotoxicity of NK Cells
01/04/2019
SOUTH SAN FRANCISCO, Calif., April 01, 2019 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held cell therapy company developing engineered Natural Killer (NK) cell therapies to fight cancer, today announced [...]
Cytokinetics to Present at April Investor Conferences
01/04/2019
SOUTH SAN FRANCISCO, Calif., April 01, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate [...]
ERYTECH Presents New Erymethionase Preclinical Findings at the 2019 AACR Annual Meeting
01/04/2019
Results support the potential for combination of erymethionase with checkpoint inhibition LYON, France and CAMBRIDGE, Mass., April 01, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a [...]
ERYTECH présente de nouveaux résultats précliniques avec erymethionase au congrès de l’AACR 2019
01/04/2019
Ces résultats démontrent le potentiel de l'association d’erymethionase avec l'inhibition des points de contrôle immunitaires LYON, France, 01 avr. 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris : ERYP - Nasdaq [...]
EB Research Partnership Announces the 3rd Annual Believe in Brady on April 7 in Houston
01/04/2019
Annual Event at Levy Park Conservancy for “Butterfly Children” with the Life-Threatening Skin Disease Epidermolysis Bullosa HOUSTON, April 01, 2019 (GLOBE NEWSWIRE) -- EB Research Partnership (EBRP), the largest [...]
Initial Results from Autolus Therapeutics’ ALLCAR19 Phase 1/2 Trial in Adult Acute Lymphoblastic Leukemia Presented at the AACR Annual Meeting
01/04/2019
Initial results from the trial show 88% molecular complete response at one month with well-tolerated safety profile Management to Hold Conference Call on April 2, 2019 at 8:00am ET / 1:00pm BST LONDON, April 01, 2019 ( [...]

Pages